Replimune Group Return on Equity

Replimune Group (REPL) currently reports a ROE of -256.55%. That is below the Healthcare sector average of -75.84%. Use the charts on this page to explore Replimune Group's ROE history and peer comparisons.

Replimune Group's ROE of -256.55% is lower than the Healthcare sector average of -75.84%. That is roughly 238.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Replimune Group's current -256.55% should be judged against Healthcare norms (sector average: -75.84%) and against REPL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -256.55%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Replimune Group, and consider following REPL for alerts when major investors trade the stock.

Replimune Group is classified in the Healthcare sector. On ROE, it currently shows -256.55% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing REPL with unrelated industries.